Drug Trial Radar · NCT07926594
Effectiveness Study of TRYPTYR in Dry Eye Disease
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 27, 2026
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Scott & Christie and Associates, PCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sengi
- First posted
- Nov 9, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, prospective, open-label, single-arm effectiveness of acoltremon 0.003% in improving patient signs and symptoms with dry eye disease. Subjects will be assessed at baseline, and after 7, 14, and 28 days of treatment. Clinical evaluations will include administration of the Eye Dryness Score Visual Analog Scale (EDS-VAS), measurement of visual acuity at distance, corneal fluorescein staining, conjunctival lissamine green staining, and Pain Numerical Rating Scale assessment.
Conditions
- Dry Eye Disease
Interventions
Acoltremon 0.003% (TRYPTYR)Drug
1 drop per eye, twice daily (morning and evening approximately 12 hours apart), at consistent times.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from Baseline in Eye Dryness Score Visual Analog Scale (EDS-VAS).Time frame: 28 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Doctor My Eyes
Scottsdale, Arizona · Recruiting
Scott & Christie and Associates, PC
Cranberry Township, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.